Skip to main content
. Author manuscript; available in PMC: 2016 Nov 15.
Published in final edited form as: Cancer Res. 2015 Sep 17;75(22):4863–4875. doi: 10.1158/0008-5472.CAN-14-2345

Figure 5.

Figure 5

Src upregulates GLUT1 expression by increasing Myc protein synthesis. A, Immunoblot shows Myc expression in vehicle- or saracatinib-treated 10A.B2 and 12A.B2 cells. B, Immunoblots showing GLUT1 and Myc in vector control, 10A.B2, 12A.B2, non-silencing (n.s.), and Myc siRNA-transfected 10A.B2 and 12A.B2 cells. C & D, qRT-PCR shows GLUT1 mRNA in vector control, 10A.B2, 12A.B2, n.s.- and Myc siRNA-transfected 10A.B2 and 12AB2 cells. E, Immunoblot showing Myc in 10A.vec, 12A.vec, 10A.B2, 12A.B2, ctrl.shRNA and Src.sh clones of 10A.B2 and 12AB2 cells. F, Immunoblot showing Myc in vector-, Src wt-, and SrcY527F-expressing MCF10A and MCF12A cells. G & H, ODs at 260 nm are shown as a function of gradient depth for 10A.B2 cells treated with vehicle or saracatinib. I & J qRT-PCR measuring Myc mRNA in the polysomal fractions of vehicle- or saracatinib-treated 10A.B2 and 12A.B2 cells. K, 10A.B2 and 12A.B2 cells were treated either with vehicle or saracatinib and immunoblotting was conducted. L, Immunoblots showing Myc and eIF4E in vector control, 10A.B2, 12A.B2, n.s.-, and eIF4E-siRNA transfected 10A.B2 and 12AB2 cells.